BioSpace News Archive

Developer of an ultrasensitive protein detection platform, Spear Bio (www.spear.bio), presented its breakthrough immunoassay technology at the recent American Association of Clinical Chemistry’s scientific meeting and clinical lab expo, held in Chicago.

Precision BioSciences, Inc. announced promotions and organizational changes that impact responsibilities within the company’s senior leadership team reporting to Michael Amoroso, Chief Executive Officer.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that Neha Krishnamohan has been appointed to the Arcutis Board of Directors and as a member of the audit committee.

InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV) will release its 2022 fiscal fourth quarter financial results on Tuesday, September 13, 2022, after market close.

Viridian Therapeutics, Inc. announced that a majority of the independent directors serving on the Compensation Committee of the Company’s Board of Directors approved the grant of stock options to purchase an aggregate of 103,000 shares of the Company’s common stock to three new employees on September 1, 2022.

Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that Monica R. Gadelha, MD, PhD, will be presenting data from a planned two-year interim analysis from the ACROBAT Advance open label extension (OLE) study at the 35th Brazilian Congress of Endocrinology and Metabolism (CBEM) being held in São Paulo, Brazil from September 3-7, 2022.

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”, “GENE”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease, is pleased to report excellent commercial progress in the USA strategic operations with the following updates.

Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., today announced multiple presentations focused on the research and treatment of lysosomal storage diseases (LSDs) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium being held in Freiburg, Germany 30 August – 2 September, 2022.

IVERIC bio, Inc. reported that on September 1, 2022, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to two newly-hired, non-executive employees.

Astria Therapeutics, Inc., a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 5,500 shares of Astria’s common stock on September 1, 2022 under Astria’s 2022 Inducement Stock Incentive Plan.